Cytogenetic and molecular genetic aspects of childhood myeloproliferative/myelodysplastic disorders

Acta Haematologica

Volumn 108, Issue 4, 2002, Pages 171-179

  Hall, Georgina W ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Childhood; Juvenile myelomonocytic leukaemia; Transient abnormal myelopoiesis

Indexed keywords

CHILDHOOD DISEASE; CHROMOSOME 5Q; CHROMOSOME 8P; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC IDIOPATHIC MYELOFIBROSIS; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE PREDISPOSITION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MOLECULAR GENETICS; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT MYELOPROLIFERATIVE DISORDER;

CHILD; CYTOGENETIC ANALYSIS; CYTOKINES; HUMANS; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS;

EID: 0036434148     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065654     Document Type: Review

References (93)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Ed 1. World Health Organization Classification of Tumours, edited by Kleihues P, Sobin L. Lyon, IARC Press, 2001.
2. Barnes DJ, Melo JV: Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol 2002;108:180-202.
3. Bain BJ: An overview of translocation-related oncogenesis in chronic myeloid leukaemias. Acta Haematol 2002;107:57-63.
4. Kaeda J, Chase A, Goldman JM: Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol 2002;107:64-75.
5. Johansson B, Fioretos T, Mitelman F: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002;107:76-94.
6. Dror Y: Essential thrombocythaemia in children. Br J Haematol 1999;107:691-698.
7. Heilmann E, Klein CE, Beck JD: Primary polycythaemia in childhood and adolescence. Folia Haematol 1983;110:935-941.
8. Sekhar M, Prentice HG, Popat U, Anderson D, Janmohammed R, Roberts I, Britt RP: Idiopathic myelofibrosis in children. Br J Haematol 1996;93:2:394-397.
9. Michiels JJ, Van Genderen PJ: Essential thrombocythemia in childhood. Semin Thromb Hemost 1997;23:295-301.
10. Yang RC, Qian LS: Essential thrombocythaemia in children: A report of nine cases. Br J Haematol 2000;110:1002-1014.
11. Siena S, Sammarelli G, Grimoldi MG, Schiavo R, Nozza A, Roncalli M, Mecucci C, Santoro A, Carlo-Stella C: New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia. Haematologica 1999;84:369-372.
12. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, Kaeda J, Cwynarski K, Goldman JM, Cross NC: Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 2000;60:3592-3598.
13. Keene P, Mendelow B, Pinto MR, Bezwoda W, MacDougall L, Falkson G, Ruff P, Bernstein R: Abnormalities of chromosome 12q13 and malignant proliferation of eosinophils: A non-random association. Br J Haematol 1987;67:25-31.
14. Borkhardt A, Bojesen S, Haas OA, Fuchs U, Bartelheimer D, Loncarevic IF, Bohle RM, Harbott J, Repp R, Jaeger U, Viehmann S, Henn T, Korth P, Scharr D, Lampert F: The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA 2000;97:9168-9173.
15. Berkowicz M, Rosner E, Rechavi G, Mamon Z, Neuman Y, Ben-Bassat I, Ramot B: Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association. Cancer Genet Cytogenet 1991;51:277-278.
16. Pellier I, LeMoine PJ, Rialland X, François S, Baranger L, Blanchet O, Larget-Piet L, Ifrah N: Myelodysplastic syndrome with t(5;12) (q31;p12-p13) and eosinophilia: A pediatric case with review of literature. J Pediatr Hematol Oncol 1996;18:285-983.
17. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-316.
18. Passmore SJ, Hann IM: Paediatric myelodysplasia. Br Med Bull 1996;52:778-786.
19. Jani K, Kempski HM, Reeves BR: A case myelodysplasia with eosinophilia having a translocation t(5;12)(q31;q13) restricted to myeloid cells but not involving eosinophils. Br J Haematol 1994;87:57-60.
20. Steer EJ, Cross NCP: Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor beta. Acta Haematol 2002;107:113-122.
21. Inhorn RC, Aster JC, Roach SA, Slapak CA, Sniffer R, Tantravahi R, Stone RM: A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): Description of a distinctive clinicopathologic entity. Blood 1995;85:1881-1887.
22. Lewis JP, Jenks H, Larzerson J: Philadelphia chromosome negative chronic myelogenous leukemia in a child with t(8;9)(p11 or 12;q34). Am J Pediatr Hematol Oncol 1983;5: 265-269.
23. Vannier JP, Bizet M, Bastard C, Bernard A, Ducastelle T, Tron P: Simultaneous occurrence of a T-cell lymphoma and a chronic myelogenous leukemia with an unusual karyotype. Leuk Res 1984;8:647-657.
24. Nakayama H, Inamitsu T, Ohga S, Kai T, Suda M, Matsuzaki A, Ueda K: Chronic myelomonocytic leukaemia with t(8;9)(p11;q34) in childhood: An example of the 8p11 myeloproliferative disorder? Br J Haematol 1996;92:692-695.
25. Sohal J, Chase A, Mould S, Corcoran M, Oscier D, Iqbal S, Parker S, Welborn J, Harris RI, Martinelli G, Montefusco V, Sinclair P, Wilkins BS, van den Berg H, Vanstraelen D, Goldman JM, Cross NC: Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer 2001; 32:155-163.
26. Macdonald D, Reiter A, Cross NCP: The 8p11 myeloproliferative syndrome: A distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002;107:101-107.
27. Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndor P, McCormick F: Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994;330:597-601.
28. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, Hass O, Harbott J, Hasle H, Kerndrup G, Locatelli F, Mann G, Stollmann-Gibbels B, van't Veer-Korthof ET, van Wering E, Zimmermann M: Chronic myelomonocytic leukemia in childhood: A retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) (see comments). Blood 1997;89:3534-3543.
29. Suda T, Miura Y, Mizoguchi H, Ijima H, Eguchi M, Kaku H, Ide C: Characterization of hemopoietic precursor cells in juvenile-type chronic myelocytic leukemia. Leuk Res 1982;6: 43-53.
30. Stiller CA, Chessells JM, Fitchett M: Neurofibromatosis and childhood leukaemia/lymphoma: A population-based UKCCSG study (see comments). Br J Cancer 1994;70:969-972.
31. Niemeyer CM, Fenu S, Hasle H, Mann G, Stary J, van Wering E: Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998;91:365-366.
32. Herrod H, Dow L, Sullivan J: Persistent Epstein-Barr virus infection mimicking juvenile chronic myelogenous leukemia: Immunologic and hematologic studies. Blood 1983;61:1098-1104.
33. Busque L, Gilliland DG, Prachal JT, Sieff CA, Weinstein HJ, Sokol JM, Belickova M, Wayne AS, Zuckerman KS, Sokol L, Castleberry RP, Emanuel PD: Clonality in juvenile chronic myelogenous leukemia. Blood 1995;85:21-30.
34. Miles DK, Freedman MH, Stephens K, Pallavicini M, Sievers EL, Weaver M, Grunberger T, Thompson P, Shannon KM: Pattern of hematopoietic lineage involvement in children with neurofibromatosis, type 1 and malignant myeloid disorders. Blood 1996;88:4314-4320.
35. Kalra R, Dale D, Freedman M, Bonilla MA, Weinblatt M, Ganser A, Bowman P, Abish S, Priest J, Oseas RS, et al: Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood 1995;86:4579-4586.
36. Miyauchi J, Asada M, Sasaki M, Tsunematsu Y, Kojima S, Mizutani S: Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 1994;83:2248-2254.
37. Miyauchi J, Asada M, Tsunematsu Y, Kaneko Y, Kojima S, Mizutani S: Abnormalities of the p53 gene in juvenile myelomonocytic leukaemia. Br J Haematol 1999;106:980-986.
38. Flotho C, Valcamonica S, Mach-Pascual S, Schmahl G, Corral L, Ritterbach J, Hasle H, Arico M, Biondi A, Niemeyer CM: RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999;13:32-37.
39. Luna-Fineman S, Shannon KM, Lange BJ: Childhood monosomy 7: Epidemiology, biology and mechanistic implications. Blood 1995; 85:1985-1999.
40. Luna-Fineman S, Shannon KM, Atwater SK, Davis J, Masterson M, Ortega J, Sanders J, Steinherz P, Weinberg V, Lange BJ: Myelodysplastic and myeloproliferative disorders of childhood: A study of 167 patients. Blood 1999;93:459-466.
41. Le Beau MM, Espinosa R 3rd, Davis EM, Eisenbart JD, Larson RA, Green ED: Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid disease. Blood 1996;88:1930-1935.
42. Brady AF, Waters CS, Pocha MJ, Brueton LA: Chronic myelomonocytic leukaemia in a child with constitutional partial trisomy 8 mosaicism. Clin Genet 2000;58:142-146.
43. Palmar CG, Profisor AJ, Weaver DD, Hodes ME, Heerema N: Juvenile chronic granulocytic leukemia in a patient with trisomy 8, neurofibromatosis and prolonged Epstein-Barr virus infection. J Pediatr 1983;102:888-892.
44. Bown N, Yule SM, Evans J, Kernahan J, Reid MM: Chronic myelomonocytic leukemia with t(13;14) in a child. Cancer Genet Cytogenet 1992;60:190-192.
45. Tosi S, Mosna G, Cazzaniga G, Giudici G, Kearney L, Biondi A, Privitera E: Unbalanced t(3;12) in a case of juvenile myelomonocytic leukemia (JMML) results in partial trisomy of 3q as defined by FISH. Leukemia 1997;11: 1465-1468.
46. Passmore SJ, Hann IM, Stiller CA, Ramani P, Swansbury GJ, Gibbons B, Reeves BR, Chessells JM: Pediatric myelodysplasia: A study of 68 children and a new prognostic scoring system. Blood 1995;85:1742-1750.
47. Shannon KM, Watterson J, Johnson P, O'Connell P, Lange B, Shah N, Steinherz P, Kann YW, Priest JR: Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: Epidemiology and molecular analysis. Blood 1992;79:1311-1318.
48. Kaneko Y, Maseki N, Sakurai M, Shibuya A, Shinohara T, Fujimoto T, Kanno H, Nishikawa A: Chromosome pattern in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis. Leukemia 1989;3:36-41.
49. Emanuel P, Bates LJ, Castleberry RP, Gaultieri RJ, Zuckerman KS: Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukaemia hematopoietic progenitors. Blood 1991;77: 925-929.
50. Freeburn RW, Gale RE, Wagner HM, Linch DC: Analysis of the coding sequence for the GM-CSF receptor alpha and beta chains in patients with juvenile chronic myeloid leukemia (JCML). Exp Hematol 1997;25:306-311.
51. Kalra R, Paderanga DC, Olson K, Shannon KM: Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 1994;84:3435-3439.
52. Brodeur GM: The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. N Engl Med 1994;330:637-639.
53. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K: Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996;12:144-148.
54. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG: Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996;12:137-143.
55. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castlebery RP, Shannon KM: Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998;92:267-272.
56. Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, Shannon K: Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997;336:1713-1720.
57. Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP: Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 2000;95: 639-645.
58. Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks F, Clapp DW, Shannon K: Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell 2000;5:189-195.
59. Bernard F, Thomas C, Emile JF, Hercus T, Cassinat B, Chomienne C, Donadieu J: Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood 2002;99:2615-2626.
60. Privitera E, Schiro R, Longoni D, Ronchi A, Rambaldi A, Bernasconi S, Ottolenghi S, Masera G, Biondi A: Constitutive expression of GATA-1, EPOR, alpha-globin, and gamma-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia. Blood 1995;86:323-328.
61. Zipursky A, Brown EJ, Christensen H, Doyle J: Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clin Lab Med 1999; 19:157-167.
62. Zipursky A, Brown E, Christensen H, Sutherland R, Doyle J: Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol 1997;21:97-101.
63. Homans AC, Verissimo AM, Vlacha V: Transient abnormal myelopoiesis of infancy associtred with trisomy 21. Am J Pediatat Hematol Oncol 1993;15:392-399.
64. Richards M, Welch J, Watmore A, Readett D, Vora AJ: Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome. Arch Dis Child (Fetal Neonatal Ed) 1998;79:F215-F217.
65. Kempsky HM, Craze JL, Chessells JM, Reeves BR: Cryptic deletions and inversions of chromosome 21 in a phenotypically normal infant with transient abnormal myelopoiesis: A molecular cytogenetic study. Br J Haematol 1998; 103:473-479.
66. Kurahashi H, Hara J, Yumura-Yagi K, Murayama N, Inoue M, Ishihara S, Tawa A, Okada S, Kawa-Ha K: Monoclonal nature of transient abnormal myelopoiesis in Down's syndrome. Blood 1991;77:1161-1163.
67. Barnett PLJ, Clark ACL, Garson OM: Acute nonlymphocytic leukemia after transient myeloproliferative disorder in a patient with Down syndrome. Med Pediatr Oncol 1990;18:347-353.
68. Kounami S, Aoyagi N, Tsuno H, Suzuki H, Kitano N, Koike M: Additional chromosome abnormalities in transient abnormal myelopoiesis in Down's syndrome patients. Acta Haematol 1997;98:109-112.
69. Zipursky A, Rose T, Skidmore M, Thorner P, Doyle J: Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatr Hematol Oncol 1996;13:81-87.
70. Al-Kasim F, Doyle JJ, Massey GV, Weinstein HJ, Zipursky: Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2002;24:9-13.
71. Arai H, Ishida A, Nakajima W, Nishinomiya F, Yamazoe A, Takada G: Immunohistochemical study on transforming growth factor-beta1 expression in liver fibrosis of Down's syndrome with transient abnormal myelopoiesis. Hum Pathol 1999;30:474-476.
72. Hattori H, Matsuzaki A, Suminoe A, Ihara K, Nakayama H, Hara T: High expression of platelet-derived growth factor and transforming growth factor-beta 1 in blast cells from patients with Down syndrome suffering from transient myeloproliferative disorder and organ fibrosis. Br J Haematol 2001;115:472-475.
73. Tsao MS: Hepatic sinusoidal fibrosis in agnogenic myeloid metaplasia. Am J Clin Pathol 1989;91:302.
74. Miyauchi J, Ito Y, Kawano T, Tsunematsu Y, Shimizu K: Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down's syndrome: A report of four autopsy cases and proposal of a hypothesis. Blood 1992;80:1521-1527.
75. Chessells JM: Myeloblastic syndromes; in Lilleyman J, Hann I, Blanchette V (eds): Pediatric Hematology. Churchill Livingstone, Edinburgh, 1999, pp 83-101.
76. Taub JW, Ravindranath Y: Down syndrome and the transient myeloproliferative disorder: Why is it transient? J Pediatr Hematol Oncol 2002;24:6-8.
77. Lin HP, Menaka H, Lim KH, Yong HS: Congenital leukemoid reaction followed by fatal leukemia: A case with Down's syndrome. Am J Dis Child 1980;134:939-941.
78. Zipursky A, Peeters M, Poon A: Megakaryoblastic leukemia and Down's syndrome - A review. Prog Clin Biol Res 1987;246:33-56.
79. Zipursky A, Poon A, Doyle J: Hematologic and oncologic disorders in Down syndrome in Lott, McCoy (eds): Down Syndrome: Advances in Medical Care. New York, Wiley-Liss, 1992, pp 93-101.
80. Yamaguchi Y, Fujii H, Kazama H, Iinamu K, Shinomiya N, Aoki T: Acute myeloblastic leukemia associated with trisomy 8 and translocation t(8;21) in a child with Down syndrome. Cancer Genet Cytogenet 1997;97:32-34.
81. Kounami S, Aoyagi N, Tsuno H, Suzuki H, Kobayashi M, Koike M: Myelodysplastic syndrome after regression of transient abnormal myelopoiesis in a Down syndrome infant: Different clonal origin? Cancer Genet Cytogenet 1998;104:115-118.
82. Kempski HM, Chessells JM, Reeves BR: Deletions of chromosome 21 restricted to the leukemic cells of children with Down syndrome and leukemia. Leukemia 1997;11:1973-1977.
83. Abe K, Kajii T, Niikawwa N: Disomic homozygosity in 21-trisomic cells: A mechanism responsible for transient myeloproliferative syndrome. Hum Genet 1989;82:313-316.
84. Niikawa N, Deng HX, Abe K, Harada N, Okada T, Tsuchiya H, Akaboshi I, Matsuda I, Fukushima T, Kaneko Y, Kuwano A, Kajii T: Possible mapping of the gene for transient myeloproliferative syndrome at 21q11.2. Hum Genet 1991;87:561-566.
85. Shen JJ, Williams BJ, Zipursky A, Doyle J, Sherman SL, Jacobs PA, Shugar AL, Soukup SW, Hassold TJ: Cytogenetic and molecular studies of Down syndrome individuals with leukaemia. Am J Hum Genet 1995;56:915-925.
86. Cavani S, Perfumo C, Argusti A, Pierluigi M, Perroni L, Schmiegelow K, Petersen MB, Cotter FE, Strigini P, Dagna-Bricarelli F, Nizetic D: Cytogenetic and molecular study of 32 Down syndrome families: Potential leukaemia predisposing role of the most proximal segment of chromosome 21q. Br J Haematol 1998;103: 213-216.
87. Gamis AS, Hilden JM: Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: Does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? J Pediatr Hematol Oncol 2002; 24:2-5.
88. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996;84:321-330.
89. Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y: Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996;87:3395-3403.
90. Holt SE, Brown EJ, Zipurksy A: Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome. J Pediatr Hematol Oncol 2002;24:14-17.
91. Yoshioka K, Yamamoto S, Moriguchi N, Miyata H, Tsukiyama K, Isokawa S, Horiuchi F, Takemura T: Overexpression of bcl-2 in transient abnormal myelopoiesis associated with Down syndrome. Ann Hematol 2000;79: 319-321.
92. Le Bousse-Kerdiles MC, Martyre MC: Involvement of the fibrogenic cytokines. TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol (Paris) 2001;49: 153-157.
93. Arico M, Biondi A, Pui CH: Juvenile myelomonocytic leukemia. Blood 1997;90:479-488.